Marizomib is a potent proteasome inhibitor and a member of the immunomodulatory drug class, primarily investigated for its therapeutic potential in treating multiple myeloma and various lymphomas. By selectively… Read more
Marizomib is a potent proteasome inhibitor and a member of the immunomodulatory drug class, primarily investigated for its therapeutic potential in treating multiple myeloma and various lymphomas. By selectively blocking the ubiquitin-proteasome pathway, this compound inhibits protein degradation, ultimately inducing apoptosis in malignant cells. Analytical laboratories rely on high-quality reference standards of Marizomib and its related compounds to ensure accurate results during drug development and manufacturing. Stable isotope labelled compounds, such as deuterated analogues, are critical tools in this process, serving as internal standards for liquid chromatography-mass spectrometry (LC-MS) to enhance the precision of quantitative analysis. Furthermore, these materials are indispensable for rigorous impurity profiling and metabolic stability studies, allowing researchers to characterize degradation pathways and validate analytical methods effectively within pharmaceutical quality control frameworks.